To include your compound in the COVID-19 Resource Center, submit it here.

The FDA-SEC tango

Bathed in congressional hot water, the FDA has pledged to make at least cosmetic efforts to deal more vigilantly with drug company promotions that shade the truth. Whether it can practically do so is another matter.

Responding to criticism from members of the House of Representatives, FDA Deputy Commissioner Lester Crawford last week disclosed that the agency will "systemize" its interactions with the Securities and Exchange Commission.

The move is geared to blunt congressional discontent over the FDA's handling of the Erbitux BLA from ImClone Systems Inc. Indeed, at last

Read the full 891 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers